Loading organizations...
Semnur Pharmaceuticals is a biopharmaceutical company focused on the clinical and commercial advancement of novel non-opioid therapies. It develops products for pain management practitioners, offering alternatives to traditional opioid solutions. The firm's approach emphasizes late-stage clinical development, aiming to bring new pharmaceutical options to market for acute and chronic pain conditions.
Specific details regarding Semnur Pharmaceuticals' founding individuals and exact inception date are not publicly available. The company operates as a wholly-owned subsidiary of Scilex Holding Company. This structure suggests an origin rooted in a broader strategy to develop specialized pharmaceutical solutions within the pain management sector, leveraging identified opportunities.
Semnur Pharmaceuticals' offerings target pain management practitioners seeking effective non-opioid treatments for their patients. Its mission is to advance therapeutic options for both acute and chronic pain, especially for individuals with significant unmet medical needs. The company envisions broadening the availability of these alternative treatments, improving patient care and outcomes.
Semnur Pharmaceuticals has raised $6.0M across 1 funding round.
Semnur Pharmaceuticals has raised $6.0M in total across 1 funding round.
Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company developing non-opioid pain management products, primarily targeting chronic back pain and sciatica. Incorporated in 2013 and headquartered in Mountain View, California, it focuses on innovative therapies like SP-102 (SEMDEXA™), a novel injectable corticosteroid gel for epidural injection in moderate to severe chronic radicular pain.[1][2][3] As a subsidiary of Scilex Holding Company, Semnur addresses underserved patients by improving efficacy and safety over traditional opioids, amid rising opioid prescriptions for back pain in the US.[3] With under 25 employees and revenue below $5 million, it operates in the manufacturing sector but emphasizes clinical and commercial development.[1][2]
Semnur Pharmaceuticals was founded in 2013, based initially in Los Altos, California, with Jaisim Shah as CEO.[2] The company emerged amid growing concerns over opioid overuse for back pain, which affects most US adults and drives high prescription rates—two to three times higher than in Europe.[3] Its lead program, SP-102 (SEMDEXA™), developed as the first preservative-free, particulate-free epidural corticosteroid gel, gained traction through clinical advancement toward FDA approval.[1][3] Now a subsidiary of Scilex Holding Company (Nasdaq: SCLX), Semnur has evolved from early development to late-stage biopharma, planning US commercialization independently or with partners, and global partnerships elsewhere.[3]
Semnur rides the non-opioid pain management trend, fueled by the US opioid crisis—over half of regular opioid users cite back pain, with prescriptions surging despite European restraint.[3] Timing aligns with FDA scrutiny on safer alternatives and post-pandemic demand for chronic pain solutions, as back pain causes widespread disability and healthcare visits.[3] Market forces like regulatory pushes for non-addictive therapies and biopharma M&A (e.g., Scilex integration) favor Semnur, influencing the ecosystem by advancing gel-based delivery tech and partnering for global reach.[1][3] It contributes to biotech's shift toward precision, low-risk injectables amid a $5.56B market cap valuation.[2]
Semnur's path hinges on FDA approval for SP-102, potentially unlocking commercialization via Scilex and partnerships, with zero current revenue but strong pipeline momentum.[2][3] Trends like AI-driven drug discovery and non-opioid mandates will shape growth, expanding into neurodegenerative/cardiometabolic via Scilex ventures.[1] Influence may grow through validated safety data, reducing opioid reliance and capturing back pain market share—positioning Semnur as a key player in safer biopharma innovation.[1][2][3]
Semnur Pharmaceuticals has raised $6.0M in total across 1 funding round.
Semnur Pharmaceuticals's investors include Canaan Partners.
Semnur Pharmaceuticals has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Venture Round in August 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2013 | $6.0M Venture Round | Canaan Partners |